Centessa Pharmaceuticals plc
CNTAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Centessa Pharmaceuticals plc focuses on Biotechnology services and products. Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. At a $6.15B market cap, Centessa Pharmaceuticals plc ranks as a mid-cap company within healthcare. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia.
Market Cap
$6.15B
Beta
1.14
P/E (TTM)
—
P/E (Fwd)
-20.95
EPS (TTM)
$-1.78
EPS (Fwd)
$-1.90
ROE
-57.4%
ROA
-27.4%
Cash
$276.6M
Total Debt
$118.6M
Free CF
-$128.7M
52W Change
196.5%
Annual Financials
Cash vs Debt
With $276.6M in cash and $118.6M in debt, CNTA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$128.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -57.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, CNTA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Centessa Pharmaceuticals plc and its sector.